Search
Evolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalIt is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering. … Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen.
Glatiramer
go.drugbank.com/drugs/DB05259ApprovedInvestigational[A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … [A248870] Originally, glatiramer acetate was designed as a stimulant of myelin basic protein (MBP), a myelin antigen involved in the development of multiple sclerosis (MS), to induce experimental autoimmune
Synonyms: (T,G)-A-LDocetaxel
go.drugbank.com/drugs/DB01248ApprovedInvestigationalDocetaxel is a complex diterpenoid molecule and a semisynthetic analogue of [paclitaxel]. … [L46466] Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.[A259676]
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: DOCETAXEL DONG-A, DOCETAXEL PHARMAKI GENERICSMannitol
go.drugbank.com/drugs/DB00742ApprovedInvestigationalAs a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. … Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables.
Categories: Compounds used in a research, industrial, or household settingSynonyms: D-Mannitol, D-(-)-MannitolEncorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalBRAF V600E or V600K mutation, as detected by an FDA-approved test. … Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations.
Tebipenem pivoxil
go.drugbank.com/drugs/DB16840ApprovedTebipenem pivoxil is an orally administered prodrug of tebipenem, a carbapenem antibacterial that kills bacteria by binding essential penicillin-binding proteins and disrupting cell wall biosynthesis. … severe or resistant Gram-negative infections but had until now been available only intravenously, meaning patients with resistant complicated urinary tract infections generally required hospitalization, a
Tulisokibart
go.drugbank.com/drugs/DB18719InvestigationalPRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and TNF superfamily member 15.
Revefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigationalThe LAMA group falls into a parent category known as long-acting inhaled bronchodilators and this type of agents are recommended as a maintenance therapy for chronic obstructive pulmonary disease (COPD … [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]
Saquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalIn 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … [A214382] While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%),[L3450] its current indications require the co-administration of ritonavir - a potent enzyme
Ixazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigationalIxazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,[A264329] it is considered a boronate proteasome inhibitor. … [A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index